乳腺的腺样鳞状细胞癌，一种罕见且预后不良的诊断——来自国家癌症数据库 12 年分析的经验教训。
Adenosquamous carcinoma of the breast, an uncommon diagnosis with poor prognosis-Lessons learned from a 12-year analysis of the National Cancer Database.
机构信息
Department of Pathology, Graduate School of Medicine, The University of Tennessee Medical Center, Knoxville, TN, USA.
Department of Surgery, Graduate School of Medicine, The University of Tennessee Medical Center, Knoxville, TN, USA.
出版信息
Breast J. 2021 Feb;27(2):165-169. doi: 10.1111/tbj.14135. Epub 2021 Jan 22.
We compared the clinicopathologic characteristics and prognosis of adenosquamous carcinoma (ASQ) of the breast with invasive ductal carcinoma (IDC), utilizing the National Cancer Database (NCDB) from 2004 to 2015. 1 932 688 female patients had invasive breast carcinoma; 1 421 250 had IDC (73.5%); and 453 had ASQ (0.0002%). When compared to IDC, ASQ patients were significantly (P < .05) older and had grade 1 tumors; negative lymph nodes; ER/PR/HER2-negative tumors; and worse 5-year overall survival (64.9% vs 74%, respectively). Our study, largest to date on ASQ, revealed an aggressive carcinoma with a significantly worse prognosis than IDC. "Personalized medicine" treatment approach for patients with this uncommon carcinoma is needed.
我们利用 2004 年至 2015 年国家癌症数据库（NCDB）比较了乳腺的腺样鳞状细胞癌（ASQ）与浸润性导管癌（IDC）的临床病理特征和预后。1932688 名女性患有浸润性乳腺癌；1421250 名患有 IDC（73.5%）；453 名患有 ASQ（0.0002%）。与 IDC 相比，ASQ 患者明显（P<.05）年龄较大，肿瘤分级为 1 级；淋巴结阴性；ER/PR/HER2 阴性肿瘤；5 年总生存率较差（分别为 64.9%和 74%）。我们的研究是迄今为止关于 ASQ 的最大研究，揭示了一种侵袭性更强、预后明显比 IDC 差的癌。需要为患有这种罕见癌的患者提供“个体化医学”治疗方法。
Zotero 插件